Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers.


Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
11 2023
Historique:
received: 21 04 2023
revised: 05 07 2023
medline: 6 11 2023
pubmed: 18 8 2023
entrez: 17 8 2023
Statut: ppublish

Résumé

Prostate-specific membrane antigen (PSMA) PET has a higher accuracy than CT and bone scans to stage patients with prostate cancer. We do not understand how to apply clinical trial data based on conventional imaging to patients staged using PSMA PET. Therefore, we aimed to evaluate the ability of bone scans to detect osseous metastases using PSMA PET as a reference standard.

Identifiants

pubmed: 37591547
pii: jnumed.123.265916
doi: 10.2967/jnumed.123.265916
doi:

Substances chimiques

Gallium Radioisotopes 0

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1744-1747

Subventions

Organisme : NCI NIH HHS
ID : R01 CA235741
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA212148
Pays : United States

Informations de copyright

© 2023 by the Society of Nuclear Medicine and Molecular Imaging.

Auteurs

Thomas A Hope (TA)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California; thomas.hope@ucsf.edu.
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.

Matthias Benz (M)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.

Fei Jiang (F)

Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California; and.

Daniel Thompson (D)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.

Francesco Barbato (F)

Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium, University Hospital Essen, Essen, Germany.

Roxana Juarez (R)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.

Miguel Hernandez Pampaloni (M)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.

Martin Allen-Auerbach (M)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.

Pawan Gupta (P)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.

Wolfgang P Fendler (WP)

Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium, University Hospital Essen, Essen, Germany.

Jeremie Calais (J)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH